OncRef

Clinical Trial: NCT06810609

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:University Hospital, Bonn
Information Provided By:University Hospital, Bonn
Last Update Posted:2026-01-27

Study Overview

Brief Summary

The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.

Official Title

Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC

Conditions

Lung Cancer Non-Small Cell Cancer (NSCLC)

Intervention / Treatment

  • Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
  • Radiation: Chemoradiotherapy
  • Drug: Immunotherapy

Other Study ID Numbers

  • ESR-21-21565
  • 2024-516367-80-00

Start Date (Actual)

2025-04-20

Primary Completion Date (Estimated)

2029-12-31

Study Completion Date (Estimated)

2030-09-30

Enrollment (Estimated)

176

Study Type

Interventional

Phase

Phase 2